Literature DB >> 2743849

Prothrombotic abnormalities in inflammatory bowel disease.

M G Conlan1, W D Haire, D A Burnett.   

Abstract

Inflammatory bowel disease (IBD) is known to be associated with a thrombotic tendency, which is often attributed to thrombocytosis, elevated fibrinogen, or decreased antithrombin III. We prospectively studied eight patients with IBD, seven of whom had little or no disease activity, to determine if they had any laboratory abnormality known to be associated with an increased risk of thrombosis. Abnormalities in fibrinolysis were noted in five patients: four with high plasminogen activator inhibitor levels and one with poor release of tissue plasminogen activator following venous occlusion. Circulating immune complexes were present in the sera of five patients. Fibrinogen was mildly elevated in one patient, and two patients had mild thrombocytosis. Decreased levels of antithrombin III, protein C, or protein S were not observed. There appears to be a high incidence of abnormalities in fibrinolysis in inactive IBD, which may contribute to the high frequency of thrombosis seen in IBD. The presence of circulating immune complexes may contribute to vascular injury and thrombosis.

Entities:  

Mesh:

Year:  1989        PMID: 2743849     DOI: 10.1007/bf01536380

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  32 in total

1.  THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS. III. COMPLICATIONS.

Authors:  F C EDWARDS; S C TRUELOVE
Journal:  Gut       Date:  1964-02       Impact factor: 23.059

2.  Vascular complications of inflammatory bowel disease.

Authors:  R W Talbot; J Heppell; R R Dozois; R W Beart
Journal:  Mayo Clin Proc       Date:  1986-02       Impact factor: 7.616

Review 3.  Thrombosis and immune disorders.

Authors:  J Vermylen; D Blockmans; B Spitz; H Deckmyn
Journal:  Clin Haematol       Date:  1986-05

4.  Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.

Authors:  G Nicoloso; J Hauert; E K Kruithof; G Van Melle; F Bachmann
Journal:  Thromb Haemost       Date:  1988-04-08       Impact factor: 5.249

Review 5.  The hypercoagulable states.

Authors:  A I Schafer
Journal:  Ann Intern Med       Date:  1985-06       Impact factor: 25.391

6.  Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor.

Authors:  I M Nilsson; H Ljungnér; L Tengborn
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-18

7.  Hemostatic alterations in inflammatory bowel disease: response to therapy.

Authors:  A M Lake; J Q Stauffer; M J Stuart
Journal:  Am J Dig Dis       Date:  1978-10

8.  Circulating immune complexes in cystic fibrosis and their correlation to clinical parameters.

Authors:  M L Disis; T L McDonald; J L Colombo; R H Kobayashi; C R Angle; S Murray
Journal:  Pediatr Res       Date:  1986-05       Impact factor: 3.756

9.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.

Authors:  A Hamsten; B Wiman; U de Faire; M Blombäck
Journal:  N Engl J Med       Date:  1985-12-19       Impact factor: 91.245

10.  Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group.

Authors: 
Journal:  Diabetes       Date:  1979-12       Impact factor: 9.461

View more
  13 in total

1.  Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation.

Authors:  Petros Zezos; Georgia Papaioannou; Nikolaos Nikolaidis; Themistoclis Vasiliadis; Olga Giouleme; Nikolaos Evgenidis
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

2.  What is the impact of resistance to activated protein C (Leiden mutation to factor V) in inflammatory bowel disease?

Authors:  Emma Attvall; Attila Frigyesi; Berit Sternby
Journal:  Int J Colorectal Dis       Date:  2006-01-13       Impact factor: 2.571

3.  Internal carotid thrombus in patients with inflammatory bowel disease: two cases.

Authors:  Sébastien Richard; Gioia Mione; Julien Perrin; Marie Toussaint-Hacquard; Jean-Christophe Lacour; Xavier Ducrocq
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

4.  Prevalence and significance of anticardiolipin antibodies in Crohn's disease.

Authors:  P Chamouard; L Grunebaum; M L Wiesel; J M Freyssinet; B Duclos; J P Cazenave; R Baumann
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199

5.  Thrombotic vascular risk factors in inflammatory bowel disease.

Authors:  M Hudson; A Chitolie; R A Hutton; M S Smith; R E Pounder; A J Wakefield
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

6.  Protein-losing enteropathy, deep venous thrombosis and pulmonary embolism in a patient with generalized inflammatory polyposis in remission stage of ulcerative colitis.

Authors:  Yoshiaki Kawaguchi; Tetsuya Mine; Ichiro Kawana; Satoshi Umemura
Journal:  Clin J Gastroenterol       Date:  2009-02-05

Review 7.  Neurology and the gastrointestinal system.

Authors:  G D Perkin; I Murray-Lyon
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-09       Impact factor: 10.154

8.  Assessment of thrombophilic abnormalities during the active state of inflammatory bowel disease.

Authors:  Maha M Maher; Somaya H Soloma
Journal:  Saudi J Gastroenterol       Date:  2008-10       Impact factor: 2.485

9.  Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease.

Authors:  J C Souto; E Martínez; M Roca; J Mateo; J Pujol; D González; J Fontcuberta
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

10.  Activated protein C resistance, thrombophilia, and inflammatory bowel disease.

Authors:  M A Heneghan; B Cleary; M Murray; T A O'Gorman; C F McCarthy
Journal:  Dig Dis Sci       Date:  1998-06       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.